Shares of IceCure Medical Ltd. (ICCM) surged about 203 percent on Wednesday morning after the company announced a 70 percent increase in its active U.S. commercial install base for ProSense, its breast cancer cryoablation system, following U.S. Food and Drug Administration marketing authorization in October 2025.
The company's shares are currently trading at $6.46 on the Nasdaq, gaining 203.29 percent in the latest session. The stock opened at $4.23 and touched an intraday high of $6.42. Over the past 12 months, the shares have traded between $2.12 and $42.00.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.